Current Report Filing (8-k)
March 22 2018 - 4:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
March 22, 2018
Northwest Biotherapeutics, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
|
0-35737
|
94-3306718
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
4800 Montgomery Lane, Suite 800
Bethesda, Maryland 20814
(Address of Principal Executive Offices)
(240) 497-9024
(Registrant’s telephone number, including
area code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
Growth Company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 7.01.
|
Regulation FD Disclosure.
|
The Company is currently exploring a potential
refinancing of its 540 acre Sawston UK property in view of a major new lease and actual and planned further improvements to the
property. In the exploration of more favorable financing terms with mortgage lenders, one party has requested that we make public
the most recent letter update of the appraisal of the property provided to us for our evaluations. With the concurrence of the
appraiser, the most recent such appraisal letter is attached hereto as Exhibit 99.1.
The Company is accommodating this request
in this instance and does not undertake any duty to provide further updates. The attached letter contains forward-looking information
in the form of assumptions, estimates, and appraisals. As with any forward-looking information, actual outcomes could differ. For
example, the economy and the real estate market in the UK, as well as the exchange rate between the British Pound Sterling and
the U.S. Dollar, could fluctuate in a manner that is difficult to anticipate.
The information contained in this Item 7.01 shall not be deemed “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the
Securities Act, except as shall be expressly set forth by specific reference in any such filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
NORTHWEST BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
Date: March 22, 2018
|
By:
|
/s/ Linda Powers
|
|
Name:
|
Linda Powers
|
|
Title:
|
Chief Executive Officer and Chairman
|
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From May 2024 to Jun 2024
Northwest Biotherapeutics (QB) (USOTC:NWBO)
Historical Stock Chart
From Jun 2023 to Jun 2024